Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Ambry Genetics, Caris Life Sciences Partner on Cancer Genetic Testing

Ambry Genetics, Caris Life Sciences Partner on Cancer Genetic Testing

Dec 04, 2019
|
staff reporter

NEW YORK – Ambry Genetics and Caris Life Sciences today announced a partnership on cancer genetic testing in the US.

Under the terms of the agreement, Caris will offer Ambry's 67-gene CancerNext-Expanded gene panel to evaluate hereditary risk of cancer alongside its Caris Molecular Intelligence tumor profiling. 

Financial and other terms of the partnership were not disclosed. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

What's Popular?

In Sequencing

  1. Natera's Signatera ctDNA Test Shows Immunotherapy Response Prediction Capability in Advanced Cancer

  2. NIH Awards $249M to Seven Firms for Rapid Acceleration of COVID-19 Diagnostics

  3. Veracyte Prices $180M Public Stock Offering

  4. Fulgent Genetics Revenues More Than Double in Q2, Driven by COVID-19 Testing

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.